About

About J R Biomedical J R Biomedical is a UK based, ISO13485 certified medical diagnostics company, who have developed a panel of proprietary antibodies, and a rapid point-of-care test to detect plasma soluble Toll-like receptor 2 (sTLR2), a biomarker known to be elevated in sepsis, and infective and non-infective inflammation. UK Patent Application GB2502531.3. The imiwn sTLR2 RAPID test gives results in 10 minutes and is UKCA certified and registered with MHRA. An independent study of sTLR2 versus CRP in critically ill patients showed that sTLR2 had better specificity and sensitivity for sepsis than C-reactive protein, the most commonly used marker in the ICU. Further, low sTLR2 levels had good ability to rule out sepsis within the first 12 h of ICU stay, when clinical parameters and traditional markers of infection are often equivocal. Global licensing and distribution opportunities for the sTLR2 antibody panel and rapid test are available.